Dr. Reddy`s Laboratories 

€70.5
125
-€1-1.4% 今天

统计数据

当日最高
70.5
当日最低
70.5
52周最高
-
52周最低
-
成交量
0
平均成交量
-
市值
12.12B
市盈率
19.81
股息收益率
0.6%
股息
0.42

即将到来

股息

0.6%股息收益率
10年增长
5.03%
5年增长
11.03%
3年增长
12.27%
1年增长
-1.34%

收益

25Oct预期
Q4 2023
Q1 2024
Q2 2024
下一个
0.81
0.85
0.89
0.92
预期每股收益
0.8962576029714887
实际每股收益
N/A

人们还关注

此列表基于关注RDDA.F的Stock Events用户的观察列表。这不是投资建议。

竞争者

这个列表是基于最近市场事件的分析。这不是投资建议。

关于

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Show more...
首席执行官
Mr. Gunupati Venkateswara Prasad B.E.
员工
27048
国家
US
ISIN
US2561352038
WKN
000659157

上市公司